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Summary
Fast and accurate delineation of acute infectious foci is very important for adequate m anagem ent of 
patients. All currently available scintigraphic techniques require a relatively long tim espan betw een  
referral to the nuclear medicine department and final diagnosis. Small peptides that bind to receptors on 
cells in the infectious focus might improve the diagnostic possibilities. Since activated leukocytes express 
somatostatin receptors, m In-octreotide, a somastostatin analogue, w as tested for its usefulness in 
detecting acute infection in rats with a calf muscle infection caused by Staphylococcus aureus. lrlIn- 
octreotide was compared with the much larger protein m In-labelled human nonspecific im m unoglobu­
lin G (n lIn-IgG). As early as 0.5 h after injection, the n l In-octreotide uptake in the abscess was 
significantly lower than that of n ,In-IgG. Moreover, no 11 ’In-octreotide retention in the abscess over 
time was noted. In conclusion, somatostatin receptor imaging does not allow scintigraphic detection of 
an acute infectious lesion. The uptake in an abscess is relatively poor compared to m In-IgG.
Introduction
Several scintigraphic techniques are currently available 
for the assessment of the presence and localization of 
infectious disease. All techniques require a relatively 
long period of time between referral to the nuclear 
medicine department and final scintigraphic diagnosis 
(more than 4 to 6 h). This timespan limits their useful­
ness in acute infection, especially when immediate 
surgical intervention is considered. Labelled autologous 
leukocyte scintigraphy, especially when labelled with 
"Tcm-hydroxymethylpropyleneamine oxime ("Tcm- 
HMPAO), may reveal acute infectious lesions within a 
few hours after administration [1]. However, prepara­
tion is rather time-consuming and cumbersome, thereby 
extending the interval between referral and final 
diagnosis [2, 3]. The use of radiolabelled proteins such 
as in In-labelled human nonspecific immunoglobulin G 
(m In-IgG) -  a large protein which accumulates non- 
specifically in infectious foci -  reduces the preparation
time to approximately 20 min [4-7], However, even in 
acute infection final scintigraphic assessment is seldom 
possible before 18 to 24 h after injection [4, 7], A novel 
approach is the use of small chemotactic peptides which 
bind to receptors in the infectious focus [8]. However, 
these potentially toxic peptides have not been studied in 
humans [8]. The use of a labelled somatostatin analogue 
could be an alternative to chemotactic peptides. Soma­
tostatin receptors are not only expressed on a wide 
variety of tumour types, but also on activated leuko­
cytes such as macrophages etc., which are of course 
abundantly present in an acute infectious focus [9, 10]. 
The radiopharmaceutical can be prepared instanta­
neously [11]. Extensive clinical testing has revealed no 
toxic side effects [9, 12, 13]. The aim of this preclinical 
study was to identify a possible role of a labelled 
somatostatin analogue, m In-octreotide, in the early 
detection of acute infection. For comparison, m In-IgG 
was used.
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Methods
Radiopharmaceuticals
The som atostatin  analogue (l l l In-DTPA-D-Phe1)- 
octreotid e w as obtained  commercially (OctreoScan 111, 
M allinckrodt M edical B.V., Petten, The N etherlands). 
R adiolabelling w ith  in In-chloride w as performed  
accord in g  to th e manufacturer's protocol. Labelling effi­
c ien cy  w a s greater than 99%.
H u m an  n on sp ecific  polyclonal IgG (Sandoglobulin, 
S a n d o z A G , N ürnberg, Germany) w as conjugated to 
diethylenetriam inepentaacetic bicyclic anhydride (bi- 
cyclic DTP A) according to the m ethod described by 
H n a to w ich  et al. [14] and labelled w ith  n l In (Indium  
ch loride, A m ersh am  International Ltd, UK). Labelling 
effic ien cy  w as greater than 95%.
Animal model
U sin g  a p rev iou sly  described m ethod, a calf m uscle 
a b scess w as in d u ced  in young, m ale random ly bred 
W istar rats (w e igh t 220-240 g) after ether anaesthesia  
w ith  approxim ately  2 x  10® colony forming units of 
Staphylococcus aureus in 0.1 ml 50:50% su spension  of 
au to lo g o u s b lood  and normal saline [15]. The animals 
w ere ran d om ly  d ivided  into two groups of four rats.
T w enty-four h ours after the inoculation of Staph, 
aureus in  the m u sc le , w hen  sw elling of the m uscle was 
apparent, 4 MBq of the respective radiopharmaceuticals 
w ere injected  v ia  th e tail vein.
Imaging protocol
A fter ether anaesthesia, rats were placed prone on  the 
gam m a camera an d  im aged 0.5, 1, 2, 4, 6 and 24 h  after 
in jection  of eith er in In-octreotide or m In-IgG. The
scintigraphic im ages were recorded w ith  a s in g le -h ea d ed  
gamma camera (Siemens Orbiter, S iem en s Inc., H o f f ­
m ann Estate, IL) equipped w ith  a p a ra lle l-h o le , 
m edium -energy collimator and connected  to a c o m p u te r  
for subsequent data analysis (A2, M edical D ata S y s te m s /  
Medtronic, A nn Arbor, MI). Sym m etric 20% w in d o w s  
were used for both the 173 and 247 keV  en ergy  p e a k s .  
Images were obtained w ith  a preset tim e o f 5 m in a n d  
stored in a 256 x  256 matrix.
The scintigraphic results w ere an alysed  b y  d r a w in g  
regions of interest over the abscess, over the n o r m a l 
contralateral calf m uscle (used as a background r e g io n ),  
over the heart (representing b lood p oo l activity) a n d  
over the w hole animal. Abscess to background r a t io s ,  
relative activity in the heart (heart to w h o le  b ody ratio X 
100%) and percentage residual activity in  the a b sc e s s  
(abscess to w hole body ratio X 100%) w ere  ca lcu la ted .
Statistical analysis
All mean values are given ±  1 standard d eviation  ( s .d . ) .  
Statistical analysis w as performed u sing  the tw o -ta iled  
Student's f-test.
Results
As show n in Fig. 1 and Table 1, retention in the w h o le  
body is significantly higher for u l In-IgG com pared t o  
m In-octreotide 2 h postinjection, indicative of ra p id  
clearance of m In-octreotide (P <  0.01). Rapid clearance  
from the blood pool is also exem plified by the re la tive  
activity in the heart 0.5 h postinjection: on ly  1.7 ±  0 .3%  
of the w hole body activity is seen  in the heart region fo r  
m In-octreotide, and 7.6 ±  0.6% for m In-IgG (P <  0 .0 1 ).
Time postinjection (h)
Fig. 1. Whole body retention in 
rats with calf muscle infection 
(mean values + 1 S.D.). For both 
groups, the activity measured 
0.5 h postinjection was set at 
100%.
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Table 1. W hole body retention in rats with calf m uscle 
infection (m ean values ±  1 S.D.). For both groups, the activity 
measured 0.5 h postinjection was set at 100%*.
Time p.i. (h) 111 In-octreotide in ln-lgG P
0.5 100+0.0 100+0.0
1 98.4+1.2 97.2±1.5 >0.10
2 88.4+12.3 96.7±0.6 >0.10
4 32.0±4.2 93.0±1.1 <0.01
6 26.1±4,1 90.4+1.0 <0.01
24 12.4±1.5 72.1±1.0 <0.01
Table 2. Percentage residual activity in the abscess in rats with  
calf muscle infection (m ean values ±  1 S.D.).
Time p.i. (h) u l ln-octreotide in ln-lgG P
0.5 5 .72+ 1 .30 8.18±1.16 <0.05
1 3 .91± 1 .05 9.44±1.28 <0.01
2 2 .47± 0 .94 10.6 1 ± 1 ,57 <0.01
4 2 .95+1 .22 12.03±1.71 <0.01
6 2 .63+0.70 14.17±1.61 <0.01
24 2 .00+0 .44 14.66±1.56 <0.01
*At 0.5 h  postinjection, the absolute count rate was not significantly 
different for b o th  groups.
One hour after injection, m In-octreotide activity in the 
heart region was indistinguishable from activity in the 
rest of the thorax.
Figure 2 and Table 2 show data on residual activity in 
the body. As early as 0.5 h postinjection, the percentage 
residual activity of m In-IgG is significantly higher than 
that of 111In-octreotide. Moreover, while m In-IgG activ­
ity in the abscesses shows a relative increase over 24 h, 
the lu In-octreotide uptake decreases more rapidly than 
the residual activity in the whole body.
Figure 3 and Table 3 show the abscess to background 
ratios over time. At 0.5 h postinjection, the ratios are 
similar for both radiopharmaceuticals. However, no 
m In-octreotide retention in the abscess can be noted: 
m In-octreotide clears as fast from abscess as from 
noninfected contralateral muscle, the latter representing 
background activity. The maximum m In-octreotide abs­
cess to background ratio in this study just exceeds 2 at 
one time point. In contrast, m In-IgG is retained in the 
abscess. It shows an increasing abscess to background 
ratio over time which finally reaches 6.08 ± 0.75 at 24 h.
Discussion
The development of an easy to perform imaging techni­
que to detect and localize acute infection within one or 
at the most a few hours has great potential for patients' 
management [16], It may help clinicians to select 
patients who need immediate invasive therapy and 
those in whom more conservative management is justi­
fied. Labelled leukocyte scintigraphy requires a rela­
tively long preparation time that is responsible for loss 
of time [1—3]. Using convenient radiopharmaceuticals 
such as m fn-IgG, a relatively long time is needed before 
a definite diagnosis can be made [4, 7]. This can be 
explained by the relatively large size of the protein, 
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Fig. 2. Percentage residual activ­
ity in  the abscess in  rats w ith calf 
m uscle infection (mean values ±  
1 S.D.).
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(h) ln-111-Octreotide ln-111-IgG
Fig. 3. Abscess to background 
ratio in rats with calf muscle 
infection (mean values ±  1 S.D.).
Table 3. Abscess to background (contralateral, noninfected 
calf muscle) ratio in rats with calf m uscle infection (mean 
values ±  1 S.D.).
Time p.i. (h) 111 In-octreotide ln In-lgG P
0.5 1.87±0.49 2.23±0.33 >0.10
1 1.67±0.48 3.23±0.46 <0.01
2 1.74±0.62 3 .45±0.27 <0.01
4 2.03±0.90 4.49±1.01 <0.02
6 1.76±0.47 4.75+0.66 <0.01
24 1.28±0.27 6.08±0.75 <0.01
tissues, thus resulting in a relatively slow increase of 
target to background ratios [15]. For these reasons, the 
development of smaller molecules with specific recep­
tors in infectious foci seems logical. One possibility is 
the use of chemotactic peptides [8], In animal studies, 
these molecules showed promising results. However, 
the step from animal to human studies is difficult 
especially due to bone marrow toxicity [8, 17], In con­
trast, m In-octreotide is a small peptide which has 
proven to be a safe radiopharmaceutical for detection of 
various types of tumour in humans [13, 14]. It shows 
rapid clearance from the blood and subsequent renal 
excretion, resulting in low background activity shortly 
after administration [18]. Theoretically, 111 In-octreotide 
could also be an attractive radiopharmaceutical for 
imaging acute infection, since activated leukocytes 
express somatostatin receptors [9,10], Unfortunately, as 
demonstrated in the present study, 111 In-octreotide 
shows only modest uptake in acute infectious foci and it
fails to accum ulate in  the focus w ith  tim e, th u s indicat­
in g  that specific retention  in the focus is ab sen t. This 
m ay be cau sed  b y  the m ainly granulocytic infiltration in  
acute staphylococcal in fection , w hile  esp ecia lly  m ac­
rophages and activated lym ph ocytes sh o w  high  
som atostatin-receptor expression . O f cou rse, sufficient  
high-affin ity  receptors are necessary to a llow  retention  
o f such rapidly clearing sm all p ep tid es in an  in fectiou s  
focu s. In contrast, specific receptors are n ot n ecessary  
for accum ulation o f n i In-IgG, since this radiopharm a­
ceutical is cleared relatively slow ly  from b lood  thus 
allow in g  a con tin u ou s su pply  of the radiolabelled pro­
tein  from the b lood  plasm a to the focus, in w hich  the 
i n In is n onsp ecifically  retained, m ost probably in a 
colloidal form  [15, 19-21]. A s sh ow n  p rev iou sly , early 
uptake in  in fectious foci in rats is su fficien t for rapid 
d elineation  [15]. H ow ever, in h um ans it is rarely p o ss­
ible to m ake a defin ite scintigraphic d iagn osis u sing  
m In-IgG in acute in fectious d isease in h u m an s earlier 
than 4 -6  h after injection of the radiopharm aceutical 
[6, 7],
A lthou gh  n ot su ited  for im aging acute in fection , there 
m ight be a role for m In-octreotide sc intigraph y in  
subacute and chronic infection. First reports indicated  
su ccessfu l d elineation  of granulom atous d isea se  [12], 
H ow ever, the n eed  for rapid scintigraphic resu lts d o es  
n o t exist in  th is type o f infection, so  com parative stu d ies  
in  patients are necessary to identify  the b est scinti­
graphic technique.
Conclusion
In conclusion, the superiority of n i In-IgG com pared  to  
m In-octreotide in  the current anim al stu d y  in d icates
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th a t111 In-octreotide in its present form is not useful for 
imaging acute bacterial infection due to the absence of 
sufficient specific accumulation in acute infectious foci. 
Our results show that there is still a need for develop­
ment of other small nontoxic peptides with high-affinity 
binding to receptors on cells that are present in large 
amounts in acute infectious foci.
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